These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 30541021)

  • 21. Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study.
    Tursi A; Mocci G; Cuomo A; Allegretta L; Aragona G; Colucci R; Della Valle N; Ferronato A; Forti G; Gaiani F; Graziani MG; Lorenzetti R; Luzza F; Paese P; Penna A; Pica R; Piergallini S; Pranzo G; Rodino S; Scarcelli A; Zampaletta C; Cicerone C; Cocco A; De' Angelis G; Donnarumma L; Franceschi M; Gallina S; Grasso G; Larussa T; Luppino I; Faggiani R; Fanigliulo L; Pagnini C; Perazzo P; Sacco R; Sebkova L; Scorza S; Serio M; De Monti A; Picchio M; Elisei W; Maconi G
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):2099-2108. PubMed ID: 33660823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study.
    Rosh JR; Turner D; Griffiths A; Cohen SA; Jacobstein D; Adedokun OJ; Padgett L; Terry NA; O'Brien C; Hyams JS
    J Crohns Colitis; 2021 Nov; 15(11):1931-1942. PubMed ID: 34037715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis on the efficacy of dual vein induction therapy of Ustekinumab in complex perianal fistulizing Crohn's disease].
    Zhang DL; Shao XX; Hu DY; Lin DP; Wu H; Jiang Y
    Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(41):3301-3306. PubMed ID: 37926575
    [No Abstract]   [Full Text] [Related]  

  • 24. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
    Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
    J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
    Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
    World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
    Hirayama H; Morita Y; Imai T; Takahashi K; Yoshida A; Bamba S; Inatomi O; Andoh A
    BMC Gastroenterol; 2022 Apr; 22(1):195. PubMed ID: 35448957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
    Wils P; Bouhnik Y; Michetti P; Flourie B; Brixi H; Bourrier A; Allez M; Duclos B; Grimaud JC; Buisson A; Amiot A; Fumery M; Roblin X; Peyrin-Biroulet L; Filippi J; Bouguen G; Abitbol V; Coffin B; Simon M; Laharie D; Pariente B;
    Clin Gastroenterol Hepatol; 2016 Feb; 14(2):242-50.e1-2. PubMed ID: 26432476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary.
    Gonczi L; Szanto K; Farkas K; Molnar T; Szamosi T; Schafer E; Golovics PA; Barkai L; Lontai L; Lovasz B; Juhasz M; Patai A; Sarang K; Vincze A; Sarlos P; Farkas A; Dubravcsik Z; Toth TG; Miheller P; Ilias A; Lakatos PL
    Dig Liver Dis; 2022 Feb; 54(2):207-213. PubMed ID: 34344576
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease.
    Melotti L; Dussias NK; Salice M; Calabrese C; Baldoni M; Scaioli E; Belluzzi A; Mazzotta E; Gionchetti P; Rizzello F
    Dig Liver Dis; 2023 Feb; 55(2):230-234. PubMed ID: 35879185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States.
    Obando C; Ding Z; Muser E; Vaidya N; Qiang W; Sun X; Wang H; Mallampati R; Xie L
    Adv Ther; 2020 May; 37(5):2127-2143. PubMed ID: 32193810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
    Li K; Friedman JR; Chan D; Pollack P; Yang F; Jacobstein D; Brodmerkel C; Gasink C; Feagan BG; Sandborn WJ; Rutgeerts P; De Hertogh G
    Gastroenterology; 2019 Oct; 157(4):1019-1031.e7. PubMed ID: 31279870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
    Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
    United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
    Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Mohl W; Teich N; Hoffstadt M; Schweitzer A; von der Ohe M; Gauss A; Atreya R; Krause T; Blumenstein I; Hartmann P; Schreiber S
    Inflamm Bowel Dis; 2023 Nov; 29(11):1741-1750. PubMed ID: 36633301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study.
    Parra RS; Chebli JMF; Queiroz NSF; Damião AOMC; de Azevedo MFC; Chebli LA; Bertges ER; Alves Junior AJT; Ambrogini Junior O; da Silva BLPS; Lubini M; Bafutto M; Flores C; Vilela EG; Boratto SF; Gasparetti Junior NLT; Steinwurz F; Carvalho NS; Féres O; da Rocha JJR
    BMC Gastroenterol; 2022 Apr; 22(1):199. PubMed ID: 35448949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.
    Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacies and Related Issues of Ustekinumab in Japanese Patients with Crohn's Disease: A Preliminary Study.
    Miyazaki T; Watanabe K; Kojima K; Koshiba R; Fujimoto K; Sato T; Kawai M; Kamikozuru K; Yokoyama Y; Hida N; Nakamura S
    Digestion; 2020; 101(1):53-59. PubMed ID: 31722356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
    Wils P; Bouhnik Y; Michetti P; Flourie B; Brixi H; Bourrier A; Allez M; Duclos B; Serrero M; Buisson A; Amiot A; Fumery M; Roblin X; Peyrin-Biroulet L; Filippi J; Bouguen G; Abitbol V; Coffin B; Simon M; Laharie D; Pariente B;
    Aliment Pharmacol Ther; 2018 Mar; 47(5):588-595. PubMed ID: 29315694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis.
    Kawalec P; Moćko P; Malinowska-Lipien I; Brzostek T
    J Comp Eff Res; 2017 Oct; 6(7):601-612. PubMed ID: 28660802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease.
    Miyatani Y; Choi D; Choi NK; Rubin DT
    Dig Dis Sci; 2024 Feb; 69(2):355-359. PubMed ID: 38112840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.